Alkermes plc. (ALKS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Alkermes plc. reported revenue of $1.48B, down 5.2% from $1.56B the year before. Net income was $241.7M (a 16.4% net margin), or $1.43 per diluted share. Gross margin was 86.7% and operating margin was 17.2%. Operating activities generated $520.8M of cash, leaving $480.3M of free cash flow. At fiscal year end, Alkermes plc. held $2.49B in total assets against $667.7M in total liabilities, including $388.6M of cash and equivalents.
Open the full interactive Alkermes plc. financials → Quarterly statements, key ratios, valuation history and price charts.
Alkermes plc. Key Stats
| Share Price | $39.73 |
|---|---|
| Market Cap | $6.89B |
| P/E Ratio | 27.8 |
| Revenue YoY Growth | -5.2% |
| 52-Week Range | $27.20 – $55.22 |
| Shares Outstanding | 167.0 million (basic, 2026 Q2) |
Alkermes plc. Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.04B | $1.17B | $1.11B | $1.66B | $1.56B | $1.48B |
| Cost of Goods Sold | $178.3M | $197.4M | $218.1M | $253.0M | $245.3M | $196.5M |
| Gross Profit | $860.4M | $976.4M | $893.7M | $1.41B | $1.31B | $1.28B |
| Operating Income | -$112.4M | -$29.3M | -$142.3M | $414.1M | $420.6M | $254.0M |
| Pre-Tax Income | -$96.5M | -$39.3M | -$167.3M | $421.5M | $443.8M | $291.4M |
| Income Tax | $14.3M | $8.9M | -$9.0M | -$97.6M | $71.6M | $49.8M |
| Net Income | -$110.9M | -$48.2M | -$158.3M | $355.8M | $367.1M | $241.7M |
| Diluted EPS | -$0.70 | -$0.30 | -$0.97 | $2.10 | $2.17 | $1.43 |
Alkermes plc. Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $394.2M | $384.5M | $392.9M | $496.0M |
| Net Income | $82.8M | $49.3M | -$66.5M | $501,000 |
| Diluted EPS | $0.49 | $0.29 | -$0.40 | — |
Alkermes plc. Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $273.0M | $337.5M | $292.5M | $457.5M | $291.1M | $388.6M |
| Current Assets | $1.11B | $1.06B | $1.13B | $1.49B | $1.42B | $1.93B |
| Total Assets | $1.95B | $2.02B | $1.96B | $2.14B | $2.06B | $2.49B |
| Current Liabilities | $438.3M | $471.3M | $497.7M | $520.2M | $465.2M | $543.4M |
| Total Long-Term Debt | $275.0M | $295.8M | $293.3M | $290.7M | — | — |
| Total Liabilities | $882.7M | $911.9M | $920.2M | $933.5M | $590.6M | $667.7M |
| Shareholders' Equity | $1.07B | $1.11B | $1.04B | $1.20B | $1.46B | $1.82B |
Alkermes plc. Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $82.8M | $101.7M | $21.0M | $401.4M | $439.1M | $520.8M |
| Cash From Investing | -$11.5M | -$66.2M | -$64.5M | $53.4M | -$111.3M | $295.5M |
| Cash From Financing | -$2.2M | $29.1M | -$1.6M | -$289.7M | -$494.1M | $12.4M |
| Free Cash Flow | $40.6M | $73.7M | -$17.2M | $353.3M | $405.6M | $480.3M |
Figures from Alkermes plc.'s 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Alkermes plc. financials page for every line item.
Alkermes plc. Company Profile
| Ticker | ALKS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Dublin 4, Ireland |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001520262 |
Frequently Asked Questions
What was Alkermes plc.'s revenue in fiscal 2025?
Alkermes plc. (ALKS) reported revenue of $1.48B for fiscal 2025.
What is Alkermes plc.'s annual revenue history?
Alkermes plc.'s annual revenue by fiscal year: 2020: $1.04B; 2021: $1.17B; 2022: $1.11B; 2023: $1.66B; 2024: $1.56B; 2025: $1.48B.
What was Alkermes plc.'s net income in fiscal 2025?
Alkermes plc. reported net income of $241.7M for fiscal 2025.
What was Alkermes plc.'s earnings per share (EPS) in fiscal 2025?
Alkermes plc.'s diluted EPS was $1.43 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Alkermes plc. generate in fiscal 2025?
Alkermes plc. generated $480.3M of free cash flow in fiscal 2025.
What was Alkermes plc.'s revenue last quarter?
In its most recent reported quarter (2026 Q2), Alkermes plc. reported revenue of $496.0M.
How many shares of Alkermes plc. are outstanding?
Alkermes plc. reported a weighted average of 167.0 million basic shares outstanding in 2026 Q2.
What is Alkermes plc.'s market cap?
Based on its latest closing price, Alkermes plc. (ALKS) has a market capitalization of about $6.89B.
When does Alkermes plc.'s fiscal year end?
Alkermes plc.'s fiscal year end, as registered with the SEC, is December 31.
Where is Alkermes plc. headquartered?
Alkermes plc. lists its business address in Dublin 4, Ireland in its SEC filings.